Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal

Applied Health Economics and Health Policy

Volumn 11, Issue 1, 2013, Pages 65-78

  Elbasha, Elamin H ^a   Chhatwal, Jagpreet ^b   Ferrante, Shannon A ^a   El Khoury, Antoine C ^a   Laires, Pedro A ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MSD Portugal   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON PLUS RIBAVIRIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GENOTYPE; HEPATITIS C; HIDDEN MARKOV MODEL; HUMAN; MALE; PORTUGAL; QUALITY OF LIFE; TREATMENT PLANNING;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MARKOV CHAINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PORTUGAL; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84873469513     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-012-0007-8     Document Type: Article

References (71)

1. World Health Organization. Hepatitis C. Fact sheet N 164, June 2011. http://www.who.int/mediacentre/factsheets/fs164/en/index.html. [Accessed 27 Mar 2012].
2. Marinho R, Giria J, Ferrinho P, Moura MC. Epidemiological aspects of hepatitis C in Portugal. J Gastroenterol Hepatol. 2001;16:1076-7.
3. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962-73.
4. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl. 2):30-60.
5. Direcção Geral de Saúde. Incidência da Hepatite C. In: Plano Nacional de Saúde 2004/2010. Vol I - Prioridades. Ministério da Saúde 2011. http://www.dgsaude.min-saude.pt/pns/ vol2-223.html [Accessed 2012 Dec 12].
6. Seeff LB. Natural history of hepatitis C. Hepatology Rev. 2005;2:88-96.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71.
8. Vieira AM, Freire R, Mangualde J, et al. Hepatite C: casuística da consulta de hepatologia de um hospital distrital. GE - J Port Gastrenterol. 2007;14:134-40.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N England J Med. 2002;347(13):975-82.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
12. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(1):68-77.
13. Poordad F, McCone J Jr, Bacon BR, SPRINT-2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
14. Bacon BR, Gordon SC, Lawitz E, HCV RESPOND-2 Investigators, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
15. Jensen DM. A new era of HCV therapy begins. N Engl J Med. 2011;364:1272-4.
16. Ferrante SA, Chhatwal J, Elbasha E, Dasbach E, Bronowicki J-P, Poordad F, et al. Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1. Hepatology. 2011;54(S1):795A-6A.
17. Chhatwal J, Ferrante SA, Dasbach E, El Khoury A, Brass C, Burroughs M, et al. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. Hepatology. 2012;54(S1):801A-2A.
18. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2003;17(5):687-94.
19. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-37.
20. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52(3):425-32.
21. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004;22(4):257-65.
22. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30(5):1318-24.
23. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-7.
24. European Medicines Agency. Annex I. summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002332/WC500109786.pdf. [Accessed 27 Mar 2012].
25. Dieterich DT, Rizzetto M, Manns MP. Management of chronic HCV: definition of relapse and nonresponse. J Viral Hepat. 2009;16(12):833-43.
26. Velosa J, Serejo F, Bana T, Redondo I, Simão A, et al. Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice. Hepatogastroenterology. 2011;58(109):1260-6.
27. Areias J, Gomes H, Mocho ML, et al. Epidemiological characterization of chronic hepatitis C in Portugal. XXI Annual Congress of the "Fundacion y Associacion Espanola para el estudio del higado", 15-17 Feb 2006; Madrid, Spain.
28. Vierling JM, Flamm SL, Gordon SC, Lawitz E, Bronowicki J, Davis M, et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study. Hepatology. 2011;54(Suppl):796A.
29. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009;136:1618-28.
30. Instituto Nacional de Estatistica, Statistics Portugal. Portuguese Life Table 2007-2009. http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine- destaques&DESTAQUESdest-boui=83112819&DESTAQUESmodo=2 [Accessed 1 Jun 2010].
31. Infarmed, Prontuário Terapêutico On-Line. 2011. http://www.infarmed.pt/prontuario/index.php [Accessed 27 Mar 2012].
32. Ministério da Saúde, Diário da República - I Série, n 16 (Portaria n 110-A/2011) de 23 de Janeiro de 2011.
33. ACSS -online catalogue. http://www.catalogo.min-saude.pt/caps/publico/ pub-consulta.asp [Accessed 27 Mar 2012].
34. Data on file, MSD Portugal, 2010.
35. INFARMED. Guidelines for Economic Drug Evaluation Studies. Nov 1998. Published in Despacho n 19064/99; 9 Sep 1999.
36. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001;4(5):348-61.
37. Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii.
38. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:iii-120.
39. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630-8.
40. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-87.
41. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and nonliver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis. 2011;53:150-7.
42. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012;54(1):96-104.
43. World Health Organization. Macroeconomics and health: investing in health for economic development: Report for the Commission on Macroeconomics and Health, Geneva, Switzerland, 2001.
44. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 2010;17(1):34-50.
45. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279-90.
46. Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al.; on behalf of the WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012 Mar 27. doi: 10.1002/hep.25734 [Epub ahead of print].
47. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739-44.
48. Pearlman B, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900.
49. Butt AA, Wang X, Moore CM. Effect of HCV and its treatment upon survival. Hepatology. 2009;50:387-92.
50. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001;15:689-98.
51. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-86.
52. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-31.
53. Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut. 2001;48(1):110-5.
54. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-72.
55. Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92(1):66-72.
56. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17 year cohort study of 214 patients. Hepatology. 2006;43:1303-10.
57. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-40.
58. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-8.
59. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328(25):1797-801.
60. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46(1):92-100.
61. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131(3):174-81.
62. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol. 2004;40(5):823-30.
63. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):1003-19.
64. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21.
65. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50(1):89-99.
66. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16(6):748-59.
67. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):961-72.
68. ACSS - Catálogo. Disponível em: http://www.catalogo.min- saude.pt/caps/publico/pub-consulta.asp [Accessed 27 Mar 2012].
69. Data on file, Merck Sharp & Dohme (MSD).
70. Base de Dados do INFARMED - Infomed. http://www.infarmed.pt/infomed/ inicio.php [Accessed 27 Mar 2012].
71. Portaria n.° 132/2009, de 30 de Janeiro - Alterada pela Portaria n.° 839 -A/2009, de 31 de Julho, e pela Portaria n.° 19/2012, de 20 de Janeiro. http://www.portaldasaude.pt/NR/rdonlyres/7A929657-9E9D-4FCC-85E1- A5DC40E64414/0/Portaria132-2009Regulamentopre%C3%A7osSNS.pdf [Accessed 27 Mar 2012].